P05-13. Fragments of HIV-1 gp41 derivatives presented on virus-like particles with preserved binding affinity for broadly neutralizing antibodies by unknown
BioMed Central
Page 1 of 1
(page number not for citation purposes)
Retrovirology
Open AccessPoster presentation
P05-13. Fragments of HIV-1 gp41 derivatives presented on 
virus-like particles with preserved binding affinity for broadly 
neutralizing antibodies
T Benen, A Kliche and R Wagner*
Address: Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany
* Corresponding author    
Background
The induction of broadly neutralizing antibodies (bNAbs)
against the envelope protein is thought to be an essential
part of an effective HIV vaccine. A part of gp41 which is
conserved through all HIV-1 clades, the membrane-proxi-
mal external region (MPER), bears epitopes for two of the
most potent known neutralizing monoclonal antibodies.
As HIV-1 virus-like particles (VLPs) provide a natural
membrane setting for gp41-derived proteins, we take
advantage of VLPs as carriers for membrane-anchored,
truncated gp41 as immunogen.
Methods
Several versions of gp41 including the C-terminal heptad
repeat (CHR), MPER, transmembrane domain and a
shortened cytoplasmic tail have been designed and char-
acterised. To stabilize the trimeric state of gp41, heterolo-
gous zipper domains have been introduced at appropriate
positions. Additionally, constructs with a further trun-
cated CHR have been designed in order to focus the
immune response to the highly conserved MPER. The
most truncated version only consists of the transmem-
brane domain and the MPER.
Results
All designed gp41 derivatives were expressed in a human
cell line and incorporated into VLPs. Most of them show
enhanced binding to bNAbs 2F5 and 4E10 compared to
full-length gp160 and similar binding compared to full-
length gp41, as measured in FACS analysis and VLP cap-
ture assay. Also the most truncated version of gp41 still
seems to be properly transported to the cellular mem-
brane and recognized by 2F5 and 4E10. All described
immunogens are currently tested in the rabbit model for
immunogenicity and elicitation of neutralizing antibod-
ies. The animals are primed with DNA and boosted two
times with VLPs presenting gp41 fragments.
Conclusion
Thus, we created several fragments of gp41 with preserved
binding affinity for broadly neutralizing antibodies, to
serve as immungens on the surface of VLPs for the elicita-
tion of antibodies directed against the membrane proxi-
mal region of gp41.
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